Home
Kelun Biotech

Kelun Biotech Market Share Analysis for June 2026

四川科伦博泰生物医药股份有限公司(6990.hk)是四川科伦药业股份有限公司(股票代码:002422)的控股子公司; 科伦博泰是一家专注于创新药物研发、制造及商业化的生物医药公司，自2016年科伦博泰成立以来，始终致力于解决中国乃至全球的医疗需求。

Industry: N/A

Domainkelun-biotech.com

Year Founded2016

Employees1001 - 5000

Annual Revenue--

Kelun Biotech

Kelun Biotech (including company regionals)

kelun-biotech.com

See more website traffic and engagement information

Total visits to Kelun Biotech's top domains

Understand Kelun Biotech market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kelun-biotech.com3K

See more with Sales Intelligence

Avg. visit duration in Kelun Biotech's top domains

Analyze Kelun Biotech engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kelun-biotech.com00:00:12

See more with Sales Intelligence

Avg. pageviews on Kelun Biotech's top domains

See how Kelun Biotech keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kelun-biotech.com1.79

See more with Sales Intelligence

Kelun Biotech top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Kelun Biotech

These are the website technologies, by industry, used by Kelun Biotech top domains

Mobile (3)

Meta Viewport

Conversion & Analytics (2)

51.la

Advertising (1)

Baidu Ads

Payment & Currencies (1)

Euro

News & Signals from Kelun Biotech

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSichuan Kelun-Biotech Biopharmaceutical Co., Ltd is developing Sacituzumab Tirumotecan on Jun 25th '26.Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

NewsHarbour Biomed partnered with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd on Jul 15th '26.According to the collaboration agreement between Harbour BioMed and Kelun-Biotech, HBM7575/SKB575 is led by Kelun-Biotech in its design, global development and commercialization, with Harbour BioMed participating in the investment and development of this asset and sharing the benefits as agreed.

NewsSichuan Kelun-Biotech Biopharmaceutical Co., Ltd partnered with Windward Bio AG on Jun 9th '26.CHENGDU, China, June 9, 2026 /PRNewswire/ - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") today announced that its partner Windward Bio has dosed the first patients in the Phase 2 SIRIUS study of SKB378/WIN378 (also known as HBM9378) in patients with chronic obstructive pulmonary disease (COPD).